Harpoon Therapeutics Announces Updated Interim Tolerability

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Luke Walker , Noura Choudhury , Nasdaq , Memorial Sloan Kettering Cancer Center , European Society Of Medical Oncology Congress , Drug Administration , Exchange Commission , Harpoon Therapeutics Inc , Harpoon Therapeutics , European Society , Medical Oncology Congress , Activating Construct , Principal Investigator , Chief Medical Officer , Orphan Drug Designation , Private Securities Litigation Reform Act , Harpoon Therapeutic ,